ARTICLE SUMMARY:
While capital is still often difficult to find for many medtech start-ups, new investors are coming into the sector and could offer options for those companies that fit the right profile. We examine the investment strategies of Koch Disruptive Technologies, the NFL Players Association, and the NIH.
For every door that closes, another opens. It has been common practice in medtech circles over the past several years to decry and bemoan the several, many—choose your adjective—venture firms that have departed the field. But if you look closely, it sometimes seems as if for every firm that quits, another takes its place.
